We only have this paper's title and publication details.
Read it at the sourcePhase III trials investigate enzalutamide outcomes in metastatic prostate cancer, indicating potential therapeutic options.
www.clinicaltrials.gov identifiers are NCT06551324 (MEVPRO-1) and NCT06629779 (MEVPRO-2).
No takes yet. Share an insight, caveat, or question.
Shore et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: